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Objective: Chronic lymphocytic inflammation with pontine perivascular enhancement 
responsive to steroids (CLIPPERS) is a rare syndrome with relapsing brainstem/
cerebellar symptoms. To examine the pathogenic processes and investigate potential 
biomarkers, we analyzed combined materials of brain and cerebrospinal fluid (CSF) by 
comprehensive methodologies.
Materials and methods: To identify major pathways of perivascular inflammation in 
CLIPPERS, we first compared the CSF proteome (n = 5) to a neurodegenerative condi-
tion, Alzheimer’s disease (AD, n = 5). Activation of complement was confirmed by immu-
nohistochemistry (IHC) on CLIPPERS brain samples (n = 3) and by ELISA in the CSF. 
For potential biomarkers, we used biomarker arrays, and compared inflammatory and 
vessel-associated proteins in the CSF of CLIPPERS (n = 5) with another inflammatory 
relapsing CNS disease, multiple sclerosis (RMS, n = 9) and healthy subjects (HS, n = 7).
results: Two hundred and seven proteins in the CSF discriminated CLIPPERS from AD. 
The complement cascade, immunoglobulins, and matrix proteins were among the most 
frequently represented pathways. Pathway analysis of upstream regulators suggested 
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the importance of vascular cell adhesion protein 1 (VCAM1), IFN-γ, interleukin (IL)-1, and 
IL-10. Differential regulation of more than 10 complement proteins of the 3 complement 
pathways in the CSF pointed to the role of complement activation. IHC on brain samples 
confirmed the perivascular complement activation, i.e., deposition of C3bc, C3d, and 
the terminal C5b-9 complement complex that partially overlapped with accumulation 
of IgG in the vessel wall. Besides endothelial cell damage, reactivity to smooth muscle 
actin was lost in the walls of inflamed vessels, but the glia limitans was preserved. The 
semi-quantitative array indicated that increased level of IL-8/CXCL8 (p < 0.05), eotaxin/
CCL11 (p < 0.01), and granulocyte colony-stimulating factor (p < 0.05) in CSF could 
distinguish CLIPPERS from HS. The quantitative array confirmed elevated concentration 
of IL-8/CXCL8 and eotaxin/CCL11 compared to HS (p <  0.05, respectively) besides 
increased levels of ICAM-1 (p < 0.05) and VCAM-1 (p < 0.001). The increased concen-
tration of VCAM-1 were able to differentiate CLIPPERS from RMS (p < 0.01), and a trend 
of elevated levels of ICAM-1 and IL-8/CXCL8 compared to RMS was also observed 
(p = 0.06, respectively).
conclusion: Complement activation, IgG deposition, and alterations of the extra-
cellular matrix may contribute to inflammation in CLIPPERS. VCAM1, ICAM1, and 
IL-8 in the CSF may differentiate CLIPPERS from RMS.
Keywords: cliPPers, proteomics, complement, cerebrospinal fluid, VcaM-1, icaM-1, interleukin-8, multiple 
sclerosis
inTrODUcTiOn
Chronic lymphocytic inflammation with pontine perivascu­
lar enhancement responsive to steroids (CLIPPERS) is a rare 
relapsing disorder with subacute brainstem features, brain 
MRI displaying multiple punctate or curvilinear foci of gado­
linium enhancement, and a clear radiological/clinical response 
to steroid treatment (1–3). Several cases have been described, 
which suggest that the typical MRI appearance can be seen 
in a variety of other disorders, including primary angiitis 
of the CNS, multiple sclerosis (MS), and lymphoma (4–8). 
Nevertheless, a homogenous group of patients has the classical 
features of CLIPPERS, and these patients do not develop other 
conditions even after a long observation period. These patients 
require long­term immunosuppression to prevent relapses, 
indicating that immune­mediated CNS inflammation is a key 
component (3).
The pathogenic mechanisms underlying the perivascular 
inflammation in CLIPPERS are largely unknown. Biopsies from 
affected areas show a predominant perivascular infiltration of 
CD3+ T cells, most of which are also CD4+ (1). This inflammation 
also expands to supratentorial brain regions that appear normal 
on 3 T MRI (1, 2, 9). CD68+ histiocytes can be present in moderate 
numbers, and infiltrating macrophages as well as a small number 
of neutrophils and eosinophils are found in some cases (2, 3, 10). 
B cells are generally seen in smaller numbers than T cells (1, 10). 
Some patients have transient or persistent oligoclonal bands 
(OCB) in the cerebrospinal fluid (CSF), suggesting that antibod­
ies may also be of importance (1, 2, 9, 11, 12). The role of B cells 
in the pathogenesis may be also indicated by cases successfully 
treated with anti­CD20 (rituximab), a B cell depletion therapy to 
treat antibody­mediated diseases (3, 13).
Novel diagnostic criteria have recently been proposed based 
on evaluation of clinical features, MRI appearance and patho­
logical examination of patients with suspected CLIPPERS. These 
criteria allow the diagnosis of definite CLIPPERS only after 
neuropathological examination and the diagnosis of possible 
CLIPPERS in patients with classical symptoms and MRI appear­
ance but without available neuropathology. These criteria might 
be useful to discriminate true CLIPPERS from the many mimics 
described (10).
In this study, we aimed at identifying possible pathogenic 
mechanisms in CLIPPERS using patients fulfilling the new diag­
nostic criteria (10). First, we examined CSF samples by proteom­
ics, and compared pathway regulations to Alzheimer’s disease 
(AD), a neurodegenerative disorder of the CNS with limited 
inflammation in order to get an overview of activated inflamma­
tory pathways in CLIPPERS. We verified major findings by other 
assays and on brain tissue from patients. To evaluate proteomics 
data as possible biomarkers, we next compared inflammatory 
and vessel­associated proteins by arrays in CLIPPERS to healthy 
controls, and then to another relapsing CNS disease, multiple 
sclerosis (RMS).
MaTerials anD MeThODs
Patients and controls
Brain biopsy, CSF, and serum samples were obtained for diagnos­
tic purposes. Pathological samples were retrospectively analyzed 
TaBle 1 | Demographics and methods used for the analysis of body fluids and tissues obtained from patients with chronic lymphocytic inflammation with pontine 
perivascular enhancement responsive to steroids.
Patient 1
Danish
Patient 2
Danish
Patient 3a/b
Danisha
Patient 4
german
Patient 5
Danishb
Demographics and clinical data
Sex/age F/58 M/42 M/60 F/69 M/62
Diagnosis 2007 2010 2013 2010 2008
Symptoms Ataxia, dysarthria, 
paresthesia
Tetraspaticity, paraparesis, 
dysarthria, diplopia, ataxia
Diplopia,  
dysarthria,  
ataxia
Diplopia, dysarthria, 
dysphagia, ataxia,  
paresthesia
Diplopia, dysarthria, 
dysphagia, ataxia
Treatment Prednisone,  
azathioprine
Prednisone,  
azathioprine
Prednisone,  
azathioprine
Methyl- 
prednisolone
Prednisone
Time of CSF collection 2014 2014 At diagnosis At diagnosis N/A
CSF, OCB None Persistent None None None
Published Ref. (11) Ref. (11) N/A Ref. (9, 14) Ref. (9)
cerebrospinal fluid
LC–MS/MSc + + +/+ + –
C3bs, TCC + + +/+
RayBiotech biomarkers + + +/+ – –
Mesoscale biomarkers + + +/+ + –
Brain
C9neo + + – – +
IgG – – – – +
C3bc, C3d, GFAP, CD31, SMA – – – – +
aSame patient with sampling at two time points.
bPatient deceased.
cNon-modified proteins and posttranslational modifications.
CSF, cerebrospinal fluid; OCB, oligoclonal bands, LC–MS/MS; liquid chromatography tandem mass spectrometry; IHC, immunohistochemistry;  
TCC, soluble terminal complement complex; SMA, smooth muscle actin.
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(Table  1). Patients #1–2 and #4–5 fulfilled the 2017 proposed 
diagnostic criteria for definite CLIPPERS (10). In patient #3a/b 
no biopsy was available, but the patient fulfilled the criteria for 
probable CLIPPERS (10).
Patients #1 and #2 with CLIPPERS
The 58­year­old woman and 42­year­old man had a relapsing 
course responding to steroids and MRI features of CLIPPERS. 
The clinical and radiological features have been described previ­
ously (11).
Patient #3a/b with CLIPPERS
The 60­year­old male was admitted in 2012 because of subacute 
ataxia, diplopia, and dysarthria. MRI revealed punctate gado­
linium enhancement in the pons and cerebellar peduncle. CSF 
obtained twice showed no OCB. Symptoms and MRI changes 
remitted after high­dose corticosteroid treatment. After a second 
corticosteroid­responsive relapse in early 2013, azathioprine was 
started. His clinical condition is stable with low­dose steroid 
(10 mg prednisone daily) and azathioprine (175 mg daily).
Patient #4 With CLIPPERS
The 69­year­old woman was diagnosed with CLIPPERS in 2010. 
The clinical findings have been described previously (9, 14).
Patient #5 With CLIPPERS
The male patient died at the age of 62 years; autopsy data have 
recently been published (9).
Control Subjects
For the examination of CSF proteome, samples from five patients 
with AD were included (15). For the examination of cytokines, 
CSF samples from nine patients with RMS (16) without immu­
notherapy and from seven subjects without CNS disease (chronic 
headache) were used.
Standard Protocol Approvals, Registrations,  
and Patient Consents
This study was carried out in accordance with the recommenda­
tions of Declaration of Helsinki with written informed consent 
from all subjects. All subjects gave written informed consent in 
accordance with the Declaration of Helsinki. The protocol was 
approved by the regional ethical committee and the Danish Data 
Protection Agency (S­20120066).
Proteomics
Sample Preparation and Labeling
Cerebrospinal fluid samples (n =  5) from patients #1–4 were 
used. Amino acid composition was analyzed for an estimation of 
total protein content, and the samples were treated with protease 
and phosphatase inhibitors. A pooled sample from patients #1 
and #3a served as sample CLIPPERS­1, and a pooled sample 
from patients #2, #3b, and #4 served as sample CLIPPERS­2. 
These samples were compared to pooled CSF samples from five 
patients with AD. Samples were ultracentrifuged, and the super­
natant was alkylated and digested (17). Peptides from each pool 
were labeled with iTRAQ reagent. After pooling of the individual 
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iTRAQ channels, the peptides were separated into (i) neutral 
glycosylated peptides; subjected to hydrophilic interaction liquid 
chromatography (HILIC) before liquid chromatography tandem 
mass spectrometry (LC–MS/MS); (ii) non­modified peptides; 
fractioned by high pH reversed phase separation into six frac­
tions and each fraction subjected to HILIC before LC–MS/MS; 
and (iii) sialylated N­linked glycopeptides and phosphorylated 
peptides; bound to TiO2 beads and subsequently analyzed using 
LC–MS/MS (17, 18).
LC–MS/MS
Peptides from the various fractions were analyzed by a nano­Easy 
LC (Thermo Fisher Scientific) coupled with a Q­Exactive mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany). All 
peptide fractions were re­suspended in 0.1% formic acid (FA) 
and loaded onto a 2 cm 100 µm inner diameter pre­column using 
the nano­Easy LC. Peptides were eluted directly onto the analyti­
cal column using a gradient of 0–34% buffer B (90% Acetonitrile, 
0.1% FA) over 30–90  min depending on the UV intensity of 
the individual HILIC fractions. All LC–MS/MS runs were 
performed using an analytical column of 20 cm × 75 µm inner 
diameter fused silica, packed with C18 material (Dr. Maisch, 
Ammerbuch­Entringen, Germany). Mass spectrometry was 
performed using higher energy collision fragmentation (HCD) 
fragmentation on a Q­Exactive instrument. MS settings: a full 
MS scan in the mass area of 400–1,800  Da was performed in 
the Orbitrap with a resolution of 70,000 FWHM and a target 
value of 1 × 106 ions. For each full scan the 12 most intense ions 
(charge states 2–5) were selected for HCD fragmentation and 
the fragments were detected at a resolution of 17,500 FWHM. 
Threshold for ion selection was 1.0e4, the AGC target value 
2.0e4, activation time was 0.1 ms, isolation window was 1.5 Da, 
and normalized collision energy was 29.
Database Search
The MS raw files were processed and searched in Mascot and 
SEQUEST through the Proteome Discoverer 2.1 software 
(Thermo Fisher Scientific) against the human Uniprot database 
using the following parameters: precursor mass tolerance of 
10 ppm; MSMS mass tolerance of 0.05 Da; enzyme: trypsin and 
up to two missed cleavages were allowed. For all data iTRAQ and 
carbamidomethylation was selected as fixed modifications. For 
the deglycosylated peptides the database search were performed 
with variable deamidation on N. When obtaining the final list of 
regulated proteins, we only used the proteins with two or more 
peptides. For the identification, the searched data were filtered to 
a threshold of 1% FDR using Percolator.
neuropathological examination
Vascular Pathology
Paraffin embedded brainstem biopsy materials from patients #1 
and #2 and autopsy material from patients #5 were stained with 
C9neo (poyclonal) and hematoxylin–eosin (HE). For positive 
controls in the C9neo stainings, biopsy samples from patients 
with anti­AQP4 seropositive neuromyelitis optica spectrum 
disorder (NMOSD) were used. Pathological specimens from 
the autopsy material (patient #5) were stained for IgG­cig and 
IgG­smi (Ventana Medical Systems, AZ, USA), GFAP (Ab6 
Thermo Fisher Scientific), CD31 (PECAM; DAKO, polyclonal), 
C3bc (bH6; Hycult), and C3d (DAKO, polyclonal).
Indirect Immunofluorescence
Twenty­micrometer cryostat sections from formalin­fixed adult 
Sprague–Dawley rat brains were blocked with 5% goat serum fol­
lowed by overnight incubation with undiluted CSF from patients 
#1–3. Following a standard washing procedure (Tris buffered 
saline), potential IgG binding was visualized with a secondary 
FITC­conjugated goat­anti­human IgG antibody (1:200, Alexa 
Flour 488, Thermofisher Scientific). Sections were counterstained 
with 10 µM 4′,6­diamidine­phenylindole dihydrochloride (DAPI, 
SigmaAldrich) and coverslipped using ProLong gold antifade 
(Thermofisher Scientific).
Binding of Isolated Serum IgG to CLIPPERS Brain
Three­micrometer brain stem sections from patient #6 were 
demasked and blocked with fetal bovine serum and were incu­
bated with undiluted serum IgG (400 µg/ml), from patients #1–3 
isolated by protein A affinity chromatography, acidic elution, 
and dialysis against PBS. Following standard washing procedure, 
sections were incubated for 2 h with HRP­conjugated rabbit anti­
human IgG antibody (1:200, DAKO P0214). After a final rinse, 
sections were developed using diaminobenzidine dehydrated 
and coverslipped using Depex mounting medium. Digital images 
were obtained using a Leica microscope (Leica 4000B LED, Leica 
Microsystems, Wetzlar, Germany) equipped with a Leica digital 
camera (Leica DFC420, Leica Microimaging).
complement activation in the csF
Activation products C3bc and soluble terminal complement 
complex (TCC) were examined in the CSF as described (19, 20).
soluble Biomarker assays
Semi-Quantitative Assay
Cerebrospinal fluid samples from patients #1–4 and three control 
subjects were applied to the RayBiotech TM Human Inflam mation 
Array C3 as described by the manufacturer.1 All samples were run 
in duplicate. Intensity of streptavidin binding was measured by 
CCD images of protein spots and subsequent measurement of 
grayscale intensity (range 0–256 AU) using NIH image analysis 
software.2
Quantitative Analysis
Cerebrospinal fluid samples used in the RayBiotech assay (patients 
#1–4) were also applied to MesoScale V­PLEX Human Biomarker 
37­Plex Kit (Mesoscale Discovery, Rockville, MD, USA). We also 
included CSF samples from seven controls and nine patients with 
RRMS. All samples were run in duplicate.
statistics
The identified and quantified peptides were imported into the 
Perseus program3 for statistic validation and t­testing to identify 
1 http://www.raybiotech.com/files/manual/Antibody­Array/AAH­INF­3.pdf.
2 https://imagej.nih.gov/nih­image/.
3 http://www.perseus­framework.org.
FigUre 1 | Proteomics of the cerebrospinal fluid in patients with chronic 
lymphocytic inflammation with pontine perivascular enhancement responsive 
to steroids (CLIPPERS). LC–MS/MS proteomics of the cerebrospinal fluid 
obtained from patients with CLIPPERS and Alzheimer disease was 
performed and compared as described in Section “Materials and Methods.” 
Heat maps of proteins discriminating between the two diseases are shown 
(red: upregulated, green: downregulated). The corresponding proteins are 
listed in Table S1 in Supplementary Material in the same order; upregulated 
proteins with functions are also indicated in Table 2.
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regulated proteins. Regulated proteins were exported and used 
for pathway analysis using the Ingenuity Pathway Analysis 
program and the STRING program.4 Proteins were used for 
quantitative analysis if they contained two or more unique 
peptides. The two­sample test was based on p­value threshold 
on 0.05. Mesoscale data were evaluated using one­way ANOVA 
with multiple comparisons and Tukey correction.
resUlTs
Proteome of the csF Obtained  
From cliPPers Patients
Altogether, 207 proteins in the CSF proteome and PTMome could 
discriminate CLIPPERS from AD: 51 proteins were upregulated 
and 156 proteins were downregulated in the CSF of patients 
with CLIPPERS (Figure 1; Table 2; Table S1 in Supplementary 
Material).
Analysis of the proteomics dataset revealed that the comple­
ment and coagulation cascades, as well as matrix proteins­ and 
4 http://string­db.org.
endothelium­related molecules, were among the most frequent 
pathways (Figure 2; Table 2; Figure S1 and Table S2 in Supplemen­
tary Material). Among the 12 top networks, molecules located 
in plasma membrane were overrepresented. Besides the comple­
ment proteins and immunoglobulins (IgGs), the network analysis 
also suggested the importance of vascular cell adhesion protein 1 
(VCAM1), cytokines IFN­γ, interleukin (IL)­1, and IL­10 (Figure 
S1 in Supplementary Material; Table 2), and these cytokines were 
also identified as upstream regulators of several differentially 
regulated proteins (Table S3 in Supplementary Material).
To gather further supporting evidence that complement acti­
vation contributes to the pathogenesis of CLIPPERS syndrome, 
we next investigated complement activation products in the CSF 
and in brain biopsy/autopsy samples of patients with CLIPPERS.
complement activation in the  
cliPPers csF
Proteomics analysis of the CSF indicated that more than 10 pro­
teins in the complement pathways were differentially regulated 
(Figure  2). To validate complement activation, we examined 
activation products in the CSF. The level of activation product 
C3bc and the soluble terminal complement complex (TCC) was 
measured in four CSF samples of three patients (#1, #2, #3a/b). 
In the CSF samples of patient #3a/b, concentration of C3bc was 
elevated (11.95 and 10.98  AU/ml; normal range 3–9  AU/ml), 
and soluble TCC was increased (0.184 and 0.117; normal range 
0–0.013 AU/ml).
complement activation in the  
cliPPers Brain
To further validate the role of activated complement cascades 
in the pathogenesis of CLIPPERS, we examined deposition of 
the membrane attack complex (MAC) by the C9neo antibody 
on brain biopsy samples from two patients (#1, #2) and autopsy 
material from another patient (#5) (Figure  3). Proteomics of 
the CSF have been also analyzed in two of these three cases 
with brain materials (#1, #2, Table  1). Biopsy samples from 
patients with anti­AQP4 seropositive NMOSD served as controls 
(Figures 3A–C). We found C9neo staining in all three CLIPPERS 
patients. In the autopsy case, C9neo was found selectively in the 
vessel wall (Figures  3D–H) mainly with little inflammation, 
likely representing very early stages (Figures  3D,E). C9neo 
reactivity was also found in vessels, in which the wall was largely 
destroyed (Figure 3F). Less C9neo reactivity was seen in vessels 
with increasing inflammation, possibly representing late stages 
(Figures 3G–I).
Vascular Pathology and Perivascular  
igg Deposition
Damage of the vessel wall was indicated by homogeneous diffuse red 
staining with HE in autopsy material from patient #5 (Figure 4A). 
GFAP staining did not show major injury of astrocytes, and glia 
limitans was preserved (Figure 4B). By contrast, partial loss of 
CD31 (PECAM) reactivity of affected vessels indicated damage of 
endothelial cells (Figure 4C). The muscular vessel wall was also 
affected: smooth muscle actin (SMA) staining was in part lost in 
TaBle 2 | Upregulated proteins in the cerebrospinal fluid of patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to 
steroids compared to patients with Alzheimer’s disease.
Protein Function
endothelial cells
Isoform 2 of Ephrin type-A receptor 8 Receptor tyrosine kinase; cell adhesion and migration
Ephrin type-A receptor 4 Receptor tyrosin kinase; vascular formation and angiogenesis in the CNS; astrocyte differentiation;  
glial cell migration
Ephrin-B1 Cell surface ligand of receptor tyrosin kinases; cell–cell adhesion
Vascular cell adhesion protein 1 (CD106) Cell adhesion and migration; ligand for VLA-4
Cell adhesion molecule 1 Cell–cell adhesion; NK cytotoxity; IFN-γ production by CD8+ T cells; risk factor for venous thrombosis
Beta-2-glycoprotein 1 Scavenges lipopolysaccharide; clears unwanted anionic cellular remnants; expressed on the surface  
and in endosomes of endothelial cells; target of antiphospholipid antibodies
Protocadherin-17 (PCDH17) Cell–cell adhesion in the CNS; inhibits migration; promotes cell cycle arrest
Multimerin-1 (MMRN1, ECM) Endothelial cell multimerin; carrier protein for platelet factors; ligand of integrins on activated platelets;  
coagulation and cell adhesion
Kallistatin Tissue kallikrein inhibitor: vascular remodeling; inhibition of endothelial apoptosis; expressed by endothelial  
and smooth muscle cells of blood vessels
Perivascular extracellular matrix
Vitronectin Binds complement C9 and inhibits C9 polymerization and formation of the membrane attack complex (regulation 
of complement activation); plasminogen activation; negative regulation of blood coagulation; cell adhesion; its 
receptor is expressed on endothelial cells; arterial wall remodeling: promotes smooth muscle migration
Decorin Inhibition of angiogenesis; binds to PDGF and inhibits its stimulatory activity on arterial smooth muscle cells
Laminin subunit gamma-1 Basement membrane assembly; cell adhesion and migration
Laminin subunit alpha-4 Regulates vascular endothelium cell survival; vessel wall formation in the skin
Extracellular matrix protein 2 ECM organization; heparin and integrin binding
Periostin Predictor of airway eosinophilia [interleukin (IL)-4, IL-13]; induced by injury in smooth muscles of the neointima 
and adventitia; vascular remodeling in experimental allergic granulomatous angiitis
Multimerin-1 Extracellular matrix adhesion; adhesion of many different cell types in vitro, including activated platelets, 
neutrophils, and endothelial cells
serum complement
Complement C3 Complement activation; central role
Complement component C9 Complement activation; part of membrane attack complex (MAC)
Complement C2 Complement activation (classic and lectin pathways)
Complement C4-A Derived from proteolysis of complement C4 (classic pathway): as anaphylatoxin induces local inflammation
C4b-binding protein beta chain Complement inhibitor: controls the classic pathway
Complement factor I Complement inhibitor: inactivates the complement components C4b and C3b
Plasma protease C1 inhibitor (SERPING1) Complement inhibitor: controls activation of the C1 complex (classic pathway)
Vitronectin Complement inhibitor: binds complement C9 and inhibits C9 polymerization and formation of the MAC
serum/plasma protein
Fibrinogen gamma chain Coagulation
Prothrombin Coagulation
Coagulation factor XI Coagulation
Plasma kallikrein Fibrinolysis, proteolysis, proinflammation and anti-angiogenesis
Alpha-2-antiplasmin Inactivates plasmin and fibrinolysis, serine protease inhibitor
Plasma serine protease inhibitor Inactivates serine proteases
Alpha-1-antichymotrypsin Protease inhibitor
Alpha-1-acid glycoprotein 1 (orosomucoid) Acute phase protein, anti-inflammatory role
Serum amyloid A-4 protein Acute phase protein
Ig kappa chain V-III region VG (fragment) Immunoglobulin (IgG)
IgG J chain IgG
Ig delta chain C region IgG
Ig lambda chain V-I region HA IgG
Ig heavy chain V-III region 23 IgG
Insulin-like growth factor-binding protein 3 (IGFBP3) Transport of IGF in the plasma
Inter-alpha-trypsin inhibitor heavy chain H1 Carries hyaluronan in plasma; may stimulate phagocytotic cells
Phospholipid transfer protein Phospholipid transfer
Haptoglobin Binds hemoglobin
Selenoprotein P Secreted glycoprotein, selenium homeostasis
Phosphatidylethanolamine-binding protein 4 Secreted protein, lysosome, extracellular exosome; promotes cellular resistance to TNF-induced apoptosis
Perivascular infiltrate and ubiquitous
V-type proton ATPase subunit S1 Ubiquitous, ion transmembrane transport
Macrophage colony-stimulating factor 1 receptor Release of pro-inflammatory cytokines by macrophages
Receptor-type tyrosine-protein phosphatase gamma Cell growth, differentiation
Cysteine-rich secretory protein 3 Neutrophil degranulation
(Continued )
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FigUre 2 | Differentially regulated complement pathways in the cerebrospinal fluid (CSF) of patients with chronic lymphocytic inflammation with pontine perivascular 
enhancement responsive to steroids (CLIPPERS). Ingenuity Pathway Analysis of the complement system in the CSF of patients with CLIPPERS. Red color indicates 
upregulation, green color indicates downregulation (see also Table 2 and Tables S1–S3 in Supplementary Material).
Protein Function
L-selectin (CD62L) Lymphocyte homing receptor
Ephrin-B1 T cell costimulation: negative feedback to TCR signals; neutrophils, macrophages and monocytes
Polypeptide N-acetylgalactosaminyltransferase 5 Protein glycosylation
Protocadherin fat 2 Membrane protein, cell adhesion
TaBle 2 | Continued
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FigUre 3 | Perivascular complement deposition in the brain of patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive  
to steroids (CLIPPERS). Autopsy and biopsy samples from patients #1–2 and #5 were analyzed (see also Table 1). (a–c) Membrane attack complex (MAC) C9neo 
(red) reactivity in positive controls from patients with active and inactive neuromyelitis optica spectrum disorder (NMOSD). (D–h) MAC C9neo reactivity in autopsy 
(patient #5). (i) C9neo reactivity in biopsy specimen (patient #2). Sections were counterstained with toluidine blue. Magnification bars represent 100 μm.
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the walls of inflamed vessels (Figure 4D). This vessel pathology 
was associated with IgG deposition (Figures 4E,I) and comple­
ment activation (C3bc, C3d, and C9neo), which was clearly 
accentuated in the vessel wall (Figures 4F–I). Reactivity with IgG 
and complement deposition partially overlapped (Figure 4I).
To investigate specific IgG binding to CNS structures, we 
incubated a pool of four CSF samples from patients #1, #2, 
and #3a/3b with rat brain tissue. Isolated serum IgG from the 
same three patients were also incubated with formalin­fixed, 
paraffin­embedded tissue obtained from patient #5. We could not 
identify specific IgG staining in any of these experiments (data 
not shown).
Potential Biomarkers of in the csF  
of cliPPers
The obtained proteomics data suggested the role of cytokines 
and integrins in network, pathway, and upstream regulator 
analyses, and we also considered endothelial stress/activation 
based on the pathology data. Therefore, we next investigated 
if these molecules may differentiate CLIPPERS from healthy 
controls and another relapsing inflammatory disease, multiple 
sclerosis (RMS).
We first compared the CSF from CLIPPERS patients to healthy 
controls by the semi­quantitative RayBiotech array. IL­8, eotaxin 
(CCL11), and granulocyte colony­stimulating factor (GCSF) 
could distinguish CLIPPERS from HS (Figure 5).
Next, we compared CSF of CLIPPERS to CSF obtained from HS 
and RMS by the quantitative MesoScale V­PLEX Kit (Figure 6). 
This confirmed that IL­8 and eotaxin (CCL11) are increased the 
CSF of patients compared to HS. In addition, VCAM­1, ICAM­1, 
serum amyloid A, and soluble fms­like tyrosine kinase­1 (Flt1/
VEGFR­1) could also distinguish CLIPPERS from HS. Elevated 
concentration of VCAM­1 distinguished the CLIPPERS CSF 
from RMS, and we also observed a trend of elevated IL­8 and 
ICAM­1 in the CSF of CLIPPERS compared to RMS (p = 0.06, 
respectively).
DiscUssiOn
Mechanisms underlying inflammation in CLIPPERS are largely 
unknown. To investigate these, we examined the proteome in 
the CSF of CLIPPERS patients compared to non­inflammatory 
brain disease AD. AD is a classic neurodegenerative disease of 
the CNS. Although the role of innate immune responses is well 
established, adaptive immune­system driven effects, mediated by 
T and B cells, appear at present to be far less important in AD 
(21). There is evidence of T cell infiltration into the brain in AD, 
nevertheless perivascular adaptive inflammatory responses are 
FigUre 5 | Molecular markers in the cerebrospinal fluid of patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive  
to steroids (CLIPPERS) compared to healthy subjects. Box-plots of molecular markers significantly upregulated in CLIPPERS CFS from patients #1–4 compared  
to healthy subjects (HS; n = 3) using the semi-quantitative RayBiotech human inflammatory assay. *p < 0.05; **p < 0.01 using Student’s t-test.
FigUre 4 | Vascular pathology in chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Immunohistochemical analysis 
of brain samples of the autopsy case (patient #5). (a) Damage of the vessel wall is indicated by staining with hematoxylin–eosin. (B) Glia limitans is preserved (GFAP 
staining). (c) Partial loss of CD31 (PECAM) reactivity from endothelia of affected vessels indicates damage of endothelial cells. (D) Reactivity with smooth muscle 
actin (SMA) staining is lost in the walls of inflamed vessels. (e) This vessel pathology is associated with immunoglobulin (IgG) reactivity. (F–h) Complement activation 
(C3bc, C3d, and C9neo) is accentuated in the vessel wall. (i) IgG reactivity and complement activation partially overlap. Magnification bars represent 100 μm.
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absent in contrast in CLIPPERS (22). In the first step, therefore we 
aimed to identify the broadest spectrum of dysregulated proteins 
comparing two CNS diseases with different pathogenesis and 
cellular responses, thus also aiming at dissecting proteins related 
to CNS tissue injury from dysregulated proteins associated with 
CLIPPERS­specific inflammation. The overrepresentation of 
dysregulated proteins related to complement activation in the 
proteome of CLIPPERS was then validated on brain samples. By 
using a broad screening approach, we next compared the CSF of 
patients from CLIPPERS to another relapsing inflammatory CNS 
disease, relapsing MS and to healthy controls in order to partially 
validate proteomics data and to identify potential biomarkers for 
CLIPPERS.
Cerebrospinal fluid proteins that were regulated differently in 
CLIPPERS compared to AD included the following: (i) proteins 
related to endothelial damage and activation including molecules 
FigUre 6 | Molecular markers in the cerebrospinal fluid (CSF) of patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive 
to steroids (CLIPPERS) compared to patients with relapsing MS and healthy subjects. Quantitative Mesoscale V-PLEX 37 human assay: differentially expressed 
biomarkers in the CSF samples from patients #1–4, compared to relapsing-remitting multiple sclerosis (RMS; n = 9) and healthy subjects (HS; n = 7). Error bars 
indicate SD. *p < 0.05; **p < 0.01, **p < 0.001, one-way ANOVA with Tukey multiple comparison test.
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involved in leukocyte recruitment (e.g., adhesion molecules, 
VCAM­1, cell adhesion molecule 1) and vascular formation/
remodeling (ephrin signaling); (ii) serum proteins, which are 
expected to reach the brain, when endothelial cells are dam­
aged (e.g., IgGs, complement, coagulation factors, acute phase 
proteins, etc.); (iii) molecules of the perivascular extracellular 
matrix important in vascular wall formation and remodeling, 
regulation of coagulation and complement activation, and cell 
adhesion (e.g., vitronectin, decorin, laminin, periostin, multi­
merin­1, and extracellular matrix protein 2); and (iv) molecules 
related to perivascular infiltrates (e.g., CSF1R). Pathway and 
network analysis also indicated the importance of coagula­
tion, cell adhesion and migration, the complement cascade, 
ephrin signaling, extracellular matrix­surface interaction, and 
contactin­mediated cell surface interactions. A network analysis 
for up­stream regulators of the differentially expressed proteins 
indicated the importance of several pro­ and anti­inflammatory 
cytokines: IFN­γ, IL­1β, TNF­β, IL­6, IL­4, and IL­10. The dif­
ferential presence of IgGs in the CSF proteome was unrelated 
to the presence of OCB; only one patient had temporary OCB 
in the CSF, and the hierarchical clustering identified similarly 
significant presence of IgGs and complement in the CSF samples 
without OCB.
We found upregulation of several key members of the com­
plement pathways in CLIPPERS CSF: C4, C4a, C4b, C2, and 
C2a (lectin and classic pathways); C3, C3a, and C3b (classic, 
lectin, and alternative pathways); and C9 (part of the terminal 
MAC). Complement activation products and the terminal 
complement complex (TCC) could be detected around plaques 
also in AD (23), but the massive dysregulation of complement 
proteins in the CLIPPERS CSF compared to AD suggested a role 
of the complement system very different from that in a classic 
neurodegenerative disease. Our data indicated activation of the 
complement system, where at least one pathway (the classical or 
lectin pathway) and potentially the alternative pathway may drive 
activation. Complement activation was verified by elevated levels 
of C3bc and the soluble TCC in the CSF, and by perivascular 
deposition of the terminal MAC in three brains. These data alto­
gether suggest the central role of complement activation in the 
pathogenesis of CLIPPERS. We also found perivascular deposi­
tion of IgG in vessels with largely destroyed walls confirming the 
CSF proteome data. Endothelial cells and the muscular vessel wall 
were primarily injured.
The deposition of complement and IgG may be a conse­
quence of vascular damage due to leakage into the perivascular 
area; however, the increased levels of soluble TCC in the CSF 
and perivascular deposition of the MAC in the brain rather 
suggest local activation. The proteome and pathological data 
indicated endothelial damage and activation, leakage of serum 
proteins, vascular inflammation, and fibrosis with dysregulated 
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perivascular extracellular matrix proteins. This may suggest 
that CLIPPERS is a form of vasculitis. The absence of vessel 
wall necrosis, granulocyte, or eosinophil infiltration does not 
support necrotizing vasculitis. Activation of the complement 
argues against an entirely T cell mediated vasculitis. If comple­
ment activation in CLIPPERS were mediated by antibodies, our 
data would suggest an antigen in the perivascular extracellular 
matrix. Autoimmunity against laminins has been described in 
autoimmune diseases (24–29), pregnancy loss (30), and Chagas 
disease (31). Complement 3 deficiency prolongs survival of 
laminin­deficient mice (32). Antibodies against laminin are able 
to fix and activate complement (33, 34). The clinical response to 
anti­CD20 (rituximab) also suggests that antibodies may play a 
role at least in some of the patients (3, 13). Still, we were unable 
to detect specific binding of IgGs by incubating brain tissue with 
CLIPPERS CSF and serum IgG with. This could be explained 
by low abundance of a given autoantibody in CSF/purified 
IgG pool from serum; nevertheless, histology of CLIPPERS 
brains indicated incomplete overlap between IgG and C9neo 
reactivity. This may argue against complement activation by 
specific autoantibodies. Two additional scenarios may explain 
complement activation: primary deficiency/local inefficiency of 
complement­regulating proteins, or alteration of extracellular 
matrix proteins that induces complement activation. We found 
downregulation of CD59 that blocks aggregation of C9 and for­
mation of the MAC. Mutations in CD59 result in recurrent brain 
infarctions and absent protein expression on brain endothelial 
cells (35). Proteolytic fragments or exposed neo­epitopes by 
altered composition of the ECM may also activate complement 
(36, 37). Decorin binds C1q, and suppresses C1q­induced 
IL­8 production by endothelial cells; biglycan binds mannose­
binding lectin and inhibits activation of the lectin pathway (38). 
Vitronectin regulates the MAC formation (39). Since a number 
of ECM proteins were differentially regulated in the CLIPPERS 
CSF proteome, complement activation by the alterations of 
ECM can be a possibility: induced by altered ECM exposing 
neo­epitopes or by leaking Ig, or C3b deposition in the presence 
of deficient inhibition by complement­regulating ECM proteins 
or CD59.
Cytokines were upregulated in the CLIPPERS CSF pro­
teome, or were among upstream regulators, including IFN­γ, 
IL­1β, and IL­10. VCAM­1 was one of the most upregulated 
proteins and was overrepresented in networks and pathways. 
Considering these data that reflect the role of cytokines and 
the possible role of endothelial stress/activation, we decided 
to use a broader array screening approach. First, we compared 
CSF levels of cytokines, chemokines, and biomarkers related to 
angiogenesis/endothelial stress to HS with a semi­quantitative 
assay, then we used a quantitative array to compare data also to 
RMS besides HS.
Upregulated VCAM­1 in the CSF could distinguish CLIPPERS 
from both HS and RMS. Increased concentration of ICAM­1 was 
also observed compared to HS and as a trend when compared to 
RMS. These are key molecules in adhesion of lymphocytes and 
monocytes. Pro­inflammatory cytokines, such as IL­8, increase 
expression of ICAM­1 and VCAM­1 by endothelial cells (40). 
Indeed, increased concentration of IL­8 (CXCL8) in the CSF 
also differentiated CLIPPERS from HS, and there was a trend of 
elevated levels compared to RMS. IL­8 is produced by endothelial 
and glial cells, and mediates chemotaxis and neutrophil effector 
functions; neuroprotective and neurotrophic functions of CXCL8 
are also emerging (41). Another chemokine eotaxin (CCL11) 
was also able to separate CLIPPERS from HS and RMS. Based 
on these findings, we suggest that upregulation of key molecules 
in chemotaxis, such as VCAM­1, ICAM­1, IL­8 (CXCL8), and 
eotaxin (CCL11) may serve as biomarkers for differentiating 
CLIPPERS from RMS. Moreover, GCSF could also differentiate 
CLIPPERS from HS and its upregulation may be a protective 
mechanism in response to inflammation (42). The tyrosine kinase 
sFlt­1 (VEGFR­1) was downregulated compared to HS. This mol­
ecule binds free placental growth factor and vascular endothelial 
growth factor, suppressing the proangiogenic effects (43). Thus, 
downregulation of sFlt­1 in CSF may indicate a net proangiogenic 
function in CLIPPERS.
This study is limited by the restricted number of patients. 
However, the number of reported cases worldwide is below 70, 
and CSF and brain samples are extremely rare. Here, we were 
able to combine analysis of both CSF and brain material, and 
in two patients, we even examined paired brain­CSF samples. 
Confirmation of results on samples from different compartments 
by other additional experiments and combination of different 
methods/compartments validating the findings strengthens the 
validity of our findings.
In conclusion, our data strongly suggest that perivascular 
complement activation is involved in the pathogenesis of 
CLIPPERS. Proteomics and molecular profiling of the CSF by 
soluble arrays points to the importance of vessel dysfunction: 
disruption of the BBB, attraction and adhesion of immune cells 
to endothelial cells, and angiogenesis. Upregulated VCAM­1, 
ICAM­1, IL­8, and eotaxin in the CSF may be potential bio­
markers in CLIPPERS; nevertheless, their differentiating role 
from RMS should be confirmed by a higher number of CSF 
samples. The cause of complement activation in CLIPPERRS 
is unclear: complement binding, alteration of the ECM, and 
search for specific antigens may be candidates for further 
studies.
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